I was very disappointed about the FDA's response regarding our CD10 trial results, for mild and moderate Covid-19. Leronlimab was, only, judged by it's performance against active Covid-19, and it's ability to help get people out of the hospital. I believe, if the patient is treated early on, they may not suffer from severe long term effects of the virus. Leronlimab's mechanism of action reduces the viral load, and enables the immune system to fight the virus as it was meant to. I've always wondered if CYDY has tracked the after effects, of the virus, in patients treated with Leronlimab. If the patients did suffer after effects, how serious were they? I bet they were slight.